These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9280606)

  • 1. [Clinical application of interleukin-6 receptor antibody].
    Nishimoto N; Shima Y; Sasai M; Danno N; Yoshizaki K
    Nihon Rinsho Meneki Gakkai Kaishi; 1997 Apr; 20(2):87-94. PubMed ID: 9280606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of humanized anti-interleukin-6 receptor antibody on new xenograft model of multiple myeloma].
    Shimazaki C; Goto H
    Rinsho Ketsueki; 1997 Apr; 38(4):281-4. PubMed ID: 9146051
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
    Nishimoto N; Sasai M; Shima Y; Nakagawa M; Matsumoto T; Shirai T; Kishimoto T; Yoshizaki K
    Blood; 2000 Jan; 95(1):56-61. PubMed ID: 10607684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
    Nishimoto N; Kishimoto T; Yoshizaki K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i21-7. PubMed ID: 11053081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
    Villunger A; Egle A; Kos M; Hittmair A; Maly K; Greil R
    Int J Cancer; 1996 Feb; 65(4):498-505. PubMed ID: 8621234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of IL-6 for the treatment of inflammatory diseases.
    Nishimoto N; Kishimoto T
    Curr Opin Pharmacol; 2004 Aug; 4(4):386-91. PubMed ID: 15251133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.
    Nishimoto N
    Clin Rev Allergy Immunol; 2005 Jun; 28(3):221-30. PubMed ID: 16129906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.
    Tsunenari T; Koishihara Y; Nakamura A; Moriya M; Ohkawa H; Goto H; Shimazaki C; Nakagawa M; Ohsugi Y; Kishimoto T; Akamatsu K
    Blood; 1997 Sep; 90(6):2437-44. PubMed ID: 9310495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6: structure-function relationships.
    Simpson RJ; Hammacher A; Smith DK; Matthews JM; Ward LD
    Protein Sci; 1997 May; 6(5):929-55. PubMed ID: 9144766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
    Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
    Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 receptor expression in the peripheral B cells of patients with multicentric Castleman's disease.
    Ishiyama T; Koike M; Nakamura S; Kakimoto T; Akimoto Y; Tsuruoka N
    Ann Hematol; 1996 Oct; 73(4):179-82. PubMed ID: 8890706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 6: from bench to bedside.
    Nishimoto N; Kishimoto T
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradigm of IL-6: from basic science to medicine.
    Naka T; Nishimoto N; Kishimoto T
    Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S233-42. PubMed ID: 12110143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The blockade of IL-6 signaling in rational drug design.
    Adachi Y; Yoshio-Hoshino N; Nishimoto N
    Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
    Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to rat soluble IL-6 receptor stimulate B9 hybridoma cell proliferation.
    Thibault V; Richards CD; Botelho F; Gauldie J
    FEBS Lett; 1997 May; 408(2):182-6. PubMed ID: 9187363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in interleukin-6 therapy].
    Ogata A; Nishimoto N; Yoshizaki K
    Rinsho Byori; 1999 Apr; 47(4):321-6. PubMed ID: 10340005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.